Wagner J C, Misinski J, Slama T G
Drug Intell Clin Pharm. 1983 Jul-Aug;17(7-8):544-6. doi: 10.1177/106002808301700710.
Two cases in which hyperbilirubinemia produced falsely elevated aminoglycoside concentrations, using the Emit assay, are described. Patients' sera were analyzed by both the Emit and a microbiologic assay. The first patient had a 26-percent greater tobramycin concentration with the Emit assay, as compared with the microbiologic assay, when the total bilirubin was 20.1 mg%. For the same patient, there was essentially no difference between the two assays when the total bilirubin was 4 mg%. The Emit concentrations in the other patient were 34-percent elevated with a total bilirubin of 9.7 mg%. Pharmacokinetic analysis also was performed on serum levels reported by each method. Calculated kinetic parameters and dosage regimens varied greatly. Patients with total bilirubin concentrations greater than 4 mg% may need to have aminoglycoside serum levels assayed by a method other than the Emit assay.
本文描述了两例使用Emit法检测时,高胆红素血症导致氨基糖苷类药物浓度假性升高的病例。患者血清同时采用Emit法和微生物学检测法进行分析。第一位患者总胆红素为20.1mg%时,Emit法检测的妥布霉素浓度比微生物学检测法高26%。对于同一患者,总胆红素为4mg%时,两种检测方法基本无差异。另一例患者总胆红素为9.7mg%时,Emit法检测的浓度升高了34%。还对每种方法报告的血清水平进行了药代动力学分析。计算得到的动力学参数和给药方案差异很大。总胆红素浓度大于4mg%的患者,可能需要采用Emit法以外的其他方法检测氨基糖苷类药物的血清水平。